Other Immunology — Sales to customers (Note 9)

Products & Services · Sales to customers (Note 9)

Johnson & Johnson Other Immunology — Sales to customers (Note 9) increased by 50.0% to $24.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 1100.0%, from $2.00M to $24.00M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2017
Last reportedQ3 2025
Rolls up toTotal Revenue

How to read this metric

An increase indicates successful market penetration or growth of secondary immunology therapies, while a decrease may signal competitive pressure or product lifecycle maturity within this specific portfolio.

Detailed definition

This metric represents the net revenue generated from the sale of pharmaceutical products within the 'Other Immunology'...

Peer comparison

Comparable to secondary immunology or specialty pharmaceutical revenue segments reported by large-cap biopharmaceutical peers, often used to track the contribution of non-blockbuster assets.

Metric ID: jnj_segment_other_immunology_sales_to_customers_note_9

Historical Data

16 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Value$17.00M$13.00M$6.00M$20.00M$12.00M$6.00M$10.00M$6.00M$4.00M$0.00$4.00M$2.00M$0.00$2.00M$16.00M$24.00M
QoQ Change-23.5%-53.8%+233.3%-40.0%-50.0%+66.7%-40.0%-33.3%-100.0%-50.0%-100.0%+700.0%+50.0%
YoY Change-29.4%-53.8%+66.7%-50.0%-33.3%-33.3%-50.0%+300.0%>999%
Range$0.00$24.00M
CAGR+9.6%
Avg YoY Growth+135.2%
Median YoY Growth-33.3%
Current Streak2+ quarters growth

Frequently Asked Questions

What is Johnson & Johnson's other immunology — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported other immunology — sales to customers (note 9) of $24.00M in Q3 2025.
How has Johnson & Johnson's other immunology — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's other immunology — sales to customers (note 9) increased by 1100.0% year-over-year, from $2.00M to $24.00M.
What does other immunology — sales to customers (note 9) mean?
Net revenue generated from the sale of specialized immunological pharmaceutical products outside of the company's primary flagship brands.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.